Pharmacological Management of Osteoporosis in Postmenopausal Women

Last updated April 8, 2022

Key Points

Key Points

Treat high risk individuals - particularly those with previous fracture.

Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.

Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.

Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.

Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.

All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.

Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.

Treatment and Management

...Treatment and Ma...

...Who to Tre...

...ne Society (ES) recommends treating p...


...Bisphosphonates...

...pausal women at high risk of fractures, ES recom...

...In postmenopausal women with osteoporosis wh...


...Denosumab...

....1: In postmenopausal women with ost...

...ostmenopausal women with osteoporosis who ar...

...postmenopausal women with osteoporosis t...


...Teriparatide an...

...enopausal women with osteoporosis at very high r...

...nopausal women with osteoporosis who have c...


...Romosozumab...

...: In postmenopausal women with osteoporosis...

...tmenopausal women with osteoporosis who have c...


Selective...

...In postmenopausal women with osteoporosis at...


...Menopausal Hormone T...

...In postmenopausal women at high ris...

...In postmenopausal women with osteoporosis...


7.1: In postmenopausal women at high ris...


...Calcium and Vitamin...

...n postmenopausal women with low BMD and...

...ostmenopausal women at high risk of fracture...


...Monitoring...

....1: In postmenopausal women with a...

...gorithm for the Management of Postmenopausal Wo...